NASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis $112.96 -1.26 (-1.10%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$112.92 -0.04 (-0.04%) As of 09/25/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GeneDx Stock (NASDAQ:WGS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GeneDx alerts:Sign Up Key Stats Today's Range$110.49▼$114.5950-Day Range$77.87▼$132.5452-Week Range$36.85▼$136.00Volume417,706 shsAverage Volume442,271 shsMarket Capitalization$3.25 billionP/E Ratio2,259.20Dividend YieldN/APrice Target$104.13Consensus RatingModerate Buy Company Overview GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting. Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care. In 2015, the company became a subsidiary of OPKO Health, leveraging OPKO’s global infrastructure to expand its testing capabilities and research collaborations. GeneDx holds College of American Pathologists (CAP) accreditation and is CLIA-certified, ensuring adherence to stringent quality and regulatory standards. GeneDx serves a diverse client base that includes hospitals, academic medical centers, reference laboratories and pharmaceutical partners, as well as patients participating in research studies. While its primary market is the United States, the company also accommodates international referrals through its global network, enabling access to advanced genetic diagnostics for clinicians and patients worldwide. With a dedicated team of geneticists, laboratory scientists and genetic counselors, GeneDx continues to advance precision medicine by translating complex genomic data into actionable clinical insights.AI Generated. May Contain Errors. Read More GeneDx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreWGS MarketRank™: GeneDx scored higher than 42% of companies evaluated by MarketBeat, and ranked 593rd out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingModerate Buy Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Downside RiskGeneDx has a consensus price target of $104.13, representing about 7.8% downside from its current price of $112.96.Amount of Analyst CoverageGeneDx has only been the subject of 3 research reports in the past 90 days.Read more about GeneDx's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth115.46% Earnings GrowthEarnings for GeneDx are expected to grow by 115.46% in the coming year, from $0.97 to $2.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is 2,259.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 280.42.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is 2,259.20, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 75.77.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 12.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GeneDx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.42% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in GeneDx has recently decreased by 3.71%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.42% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in GeneDx has recently decreased by 3.71%, indicating that investor sentiment is improving. News and Social Media2.1 / 5News Sentiment0.70 News SentimentGeneDx has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.02 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for GeneDx this week, compared to 12 articles on an average week.Search InterestOnly 7 people have searched for WGS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $69,280,301.00 in company stock.Percentage Held by Insiders29.60% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GeneDx's insider trading history. Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WGS Stock News HeadlinesGeneDx (NASDAQ:WGS) CFO Sells $452,840.16 in StockSeptember 19, 2025 | insidertrades.comGeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National ConferenceSeptember 25 at 8:00 AM | businesswire.comThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he’s kneecapped the Federal Reserve… | Banyan Hill Publishing (Ad)Stocks With Rising Relative Price Strength: Omada HealthSeptember 23 at 4:56 PM | msn.comEli Lilly’s (LLY) AI Chief Joins the Board of GeneDxSeptember 19, 2025 | msn.comGeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of DirectorsSeptember 18, 2025 | finance.yahoo.comGeneDx Holdings Appoints Thomas Fuchs to BoardSeptember 18, 2025 | tipranks.comGeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of DirectorsSeptember 18, 2025 | businesswire.comSee More Headlines WGS Stock Analysis - Frequently Asked Questions How have WGS shares performed this year? GeneDx's stock was trading at $76.86 at the beginning of 2025. Since then, WGS stock has increased by 47.0% and is now trading at $112.96. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) released its quarterly earnings results on Tuesday, July, 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.40. The company had revenue of $102.69 million for the quarter, compared to analyst estimates of $86 million. GeneDx had a trailing twelve-month return on equity of 16.51% and a net margin of 0.39%. Read the conference call transcript. When did GeneDx's stock split? GeneDx shares reverse split on the morning of Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GeneDx's major shareholders? GeneDx's top institutional investors include William Blair Investment Management LLC (5.72%), Westfield Capital Management Co. LP (2.05%), Zweig DiMenna Associates LLC (2.05%) and Invesco Ltd. (1.93%). Insiders that own company stock include Keith A Meister, Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Katherine Stueland, Jason Ryan, Kevin Feeley and Karen Ann White. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeneDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings7/29/2025Today9/25/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:WGS CIK1818331 Websema4.com Phone800-298-6470FaxN/AEmployees1,200Year Founded2000Price Target and Rating Average Price Target for GeneDx$104.13 High Price Target$140.00 Low Price Target$80.00 Potential Upside/Downside-7.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$0.05 Trailing P/E Ratio75.14 Forward P/E Ratio116.45 P/E GrowthN/ANet Income-$52.29 million Net Margins0.39% Pretax Margin0.42% Return on Equity16.51% Return on Assets9.35% Debt Debt-to-Equity Ratio0.19 Current Ratio2.87 Quick Ratio2.70 Sales & Book Value Annual Sales$305.45 million Price / Sales10.62 Cash Flow$1.01 per share Price / Cash Flow111.62 Book Value$8.75 per share Price / Book12.91Miscellaneous Outstanding Shares28,730,000Free Float20,223,000Market Cap$3.25 billion OptionableOptionable Beta2.04 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:WGS) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.